Actively Recruiting
The Prognosis of Patients After PCI：a Multi-center Study in China
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-06-26
2400
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
U
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor
S
Shandong Provincial Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Coronary artery disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular and cerebrovascular events (MACCE). At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Previous studies indicated that hsCRP ≥ 2mg / L was the definition standard of RIR in CAD in European and American people. In China, the impact of dynamic changes of hsCRP and other inflammatory factors on MACCE in PCI population remains unclear. Therefore, in this study, the investigators plan to recruit patients undergoing PCI, and observe the impact of hsCRP and other inflammatory factors on the prognosis of these patients during long term follow-up at 17 hospitals in China.
CONDITIONS
Official Title
The Prognosis of Patients After PCI：a Multi-center Study in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants who understand and sign the informed consent voluntarily
- Age 18 years old and 80 years old or younger, regardless of sex
- Hospitalized patients with coronary heart disease undergoing PCI
- Completed all planned PCI procedures during hospitalization
You will not qualify if you...
- Acute, chronic or recurrent infectious diseases
- Immune diseases or immune-related diseases
- Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory or chemotherapy drugs
- Pregnant women, lactating women or women of childbearing age not using effective contraceptive measures
- Other conditions determined by researchers that make the patient unsuitable for the clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022
Actively Recruiting
Research Team
M
Miao Yu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here